3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Brain Neoplasms
3
Multiple Myeloma
2
Lymphoma
2
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Localized, Operable Non-small Cell Lung Cancer
1
Liver Neoplasms
1
Liver Diseases
1
Fibrosis
1
Fatigue
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Cancer Related Cognitive Difficulties
1
Breast Neoplasms
1
Interventions
Fulvestrant
126
Trastuzumab
116
Paclitaxel
113
Letrozole
108
pembrolizumab
80
palbociclib
76
pertuzumab
75
Capecitabine
75
Anastrozole
72
Cyclophosphamide
70
Carboplatin
67
abemaciclib
65
exemestane
63
Tamoxifen
63
ribociclib
61
trastuzumab deruxtecan
58
Surveys and Questionnaires
51
Specimen Handling
51
Radiotherapy
50
Docetaxel
49
Magnetic Resonance Spectroscopy
48
Blood Specimen Collection
41
olaparib
40
Standard of Care
36
Biopsy
33
sacituzumab govitecan
32
130-nm albumin-bound paclitaxel
32
Exercise
30
Doxorubicin
30
eribulin
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Neuropsychological Tests
×
1 year
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled